GAMMA Investing LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 6,981.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 224,702 shares of the company's stock after buying an additional 221,529 shares during the quarter. GAMMA Investing LLC owned 0.06% of Moderna worth $6,370,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after purchasing an additional 388 shares in the last quarter. Yousif Capital Management LLC raised its holdings in Moderna by 3.9% during the 4th quarter. Yousif Capital Management LLC now owns 42,171 shares of the company's stock worth $1,753,000 after buying an additional 1,568 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Moderna by 1.9% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 34,863 shares of the company's stock valued at $1,450,000 after buying an additional 657 shares in the last quarter. Apollon Wealth Management LLC boosted its holdings in shares of Moderna by 27.6% in the fourth quarter. Apollon Wealth Management LLC now owns 6,460 shares of the company's stock valued at $269,000 after buying an additional 1,396 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after acquiring an additional 587 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.
Moderna Stock Performance
Shares of MRNA stock traded down $0.46 during trading on Tuesday, hitting $27.68. The company had a trading volume of 7,880,867 shares, compared to its average volume of 8,309,185. The firm has a market capitalization of $10.71 billion, a P/E ratio of -2.98 and a beta of 1.86. Moderna, Inc. has a one year low of $23.15 and a one year high of $152.28. The stock's 50-day moving average price is $26.12 and its 200 day moving average price is $33.35.
Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period in the prior year, the firm posted ($3.07) EPS. Moderna's quarterly revenue was down 35.3% on a year-over-year basis. On average, research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Royal Bank of Canada cut their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. JPMorgan Chase & Co. dropped their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research note on Thursday, May 22nd. Evercore ISI reduced their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Barclays lowered their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. Finally, Morgan Stanley decreased their target price on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $53.58.
View Our Latest Stock Report on MRNA
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
